News

News

FDA Recalls Three Hematology Analyzers

The FDA issued a Class I recall of three hematology analyzers – Beckman Coulter DxH 800, DxH 600, and DxH 900 – after reports...
WIB_icon

Walking Speed Predicts Frailty, Survival, and Other Outcomes in Older Patients With Blood Cancers

Walking speed was a reliable indicator of frailty among older patients with blood cancers, and this frailty measure was a more accurate predictor of...

Tagraxofusp Leads to High Response Rates in Blastic Plasmacytoid Dendritic Cell Neoplasm

Ninety percent of patients with previously untreated blastic plasmacytoid dendritic cell neoplasm (BPDCN) responded to treatment with tagraxofusp, a CD123-targeted agent previously known as...

Study Finds Standard R-CHOP Bests Dose-Adjusted EPOCH-R in DLBCL

In an update from the phase III intergroup Alliance/CALGB 50303 trial, treatment with frontline dose-adjusted (DA) EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab) failed...

TKIs Linked to Increased Cardiovascular and Arteriothrombotic Events in Chronic-Phase CML

In patients with chronic-phase chronic myeloid leukemia (CML), treatment with tyrosine kinase inhibitors (TKIs) has been shown to increase the risk of cardiovascular and...

FDA to Close Its Controversial Medical Device Reporting Program

In what is being called a victory for patients and consumers, the U.S. Food and Drug Administration (FDA) said that it is ending its...
ASH Directions

New ASH Congressional Fellow, Accepting Submissions for 2019 ASH Annual Meeting, and more

Next ASH Congressional Fellow Is Bound for Capitol Hill Zachary Kiser, PhD, has been selected by the American Society of Hematology (ASH) to be the...

FDA Expands Ivosidenib’s Indication to Newly Diagnosed AML

On May 2, 2019, The U.S. Food and Drug Administration (FDA) approved an expanded indication for the IDH1 inhibitor ivosidenib to include the treatment...
WIB_icon

Post-Transplant Pembrolizumab Consolidation Improves PFS in Relapsed/Refractory Hodgkin Lymphoma

In patients with high-risk, relapsed/refractory classical Hodgkin lymphoma (cHL) who have undergone autologous hematopoietic cell transplantation (AHCT), consolidation therapy with the PD-1 inhibitor pembrolizumab...
WIB_icon

New Study Supports “R2” Regimen in Previously Untreated Follicular Lymphoma

The combination of lenalidomide and rituximab, known as the R2 regimen, improved progression-free survival (PFS), time to next treatment (TTNT), and complete response (CR)...
Advertisement

Current Issue

August 2019, Volume 5, Issue 10

August 2019, Volume 5, Issue 10

This issue features a debate about gun control as a health care issue, a look at blood services in Israel and Palestine, and more.